| Not Yet Recruiting | Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen NCT07055295 | Sinovac Biotech Co., Ltd | Phase 3 |
| Active Not Recruiting | A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10 to 60 NCT07275645 | Ab&B Bio-tech Co., Ltd.JS | Phase 3 |
| Not Yet Recruiting | Safety and Immunogenicity of ID vs IM Rabies Vaccine NCT07345208 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 2 / Phase 3 |
| Not Yet Recruiting | Safety and Immunogenicity of Coadministration of the Candidate Rabies Vaccine ChAdOx2 RabG and Licensed Vaccin NCT07168018 | University of Oxford | Phase 2 |
| Not Yet Recruiting | Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells) NCT07028801 | Ningbo Rongan Biological Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell) NCT07055880 | Sinovac Biotech Co., Ltd | Phase 2 |
| Completed | Adherence to Anti-rabies Post-exposure Prophylactic Protocols NCT07012083 | Tanta University | — |
| Recruiting | A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried NCT07021703 | Ningbo Rongan Biological Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow F NCT06998004 | AstriVax Therapeutics | Phase 1 |
| Completed | A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried in a Population Aged 10-60 Ye NCT06132789 | Ab&B Bio-tech Co., Ltd.JS | Phase 1 |
| Unknown | A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried NCT05667974 | Yisheng Biopharma (Singapore) Pte. Ltd. | Phase 3 |
| Unknown | Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells) NCT05969626 | Ningbo Rongan Biological Pharmaceutical Co., Ltd. | Phase 3 |
| Terminated | Survey of Human Rabies Immune Globulin Safety in Children NCT05382650 | The Methodist Hospital Research Institute | — |
| Unknown | Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabi NCT05453487 | China National Biotec Group Company Limited | Phase 4 |
| Completed | Social Media as an Information, Education and Communication Tool for Rabies Prevention: An Interventional Stud NCT05702008 | Maulana Azad Medical College | N/A |
| Active Not Recruiting | A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG NCT04270838 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Immunity Persistence After Abridged Intradermal Rabies PEP NCT04829630 | Institut Pasteur | N/A |
| Completed | A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety NCT04644484 | Synermore Biologics (Suzhou) Co., Ltd. | Phase 3 |
| Completed | Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intraderma NCT06433440 | University of Peshawar | Phase 4 |
| Completed | Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intrade NCT05937113 | Vietnam Military Medical University | Phase 4 |
| Unknown | Immunological Tolerance After Frequent Rabies Booster Vaccinations NCT03729102 | Queen Saovabha Memorial Institute | N/A |
| Terminated | Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG NCT04162600 | University of Oxford | Phase 1 |
| Completed | Improving Adherence to Rabies PEP Guideline Recommendations NCT04213950 | The Methodist Hospital Research Institute | N/A |
| Completed | Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vacci NCT05547815 | Changchun Zhuoyi Biological Co., Ltd | Phase 4 |
| Completed | Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Reg NCT04127786 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparat NCT04019444 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies NCT03961555 | Synermore Biologics Co., Ltd. | Phase 2 |
| Completed | A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in NCT03713086 | CureVac | Phase 1 |
| Completed | Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project NCT05350735 | Washington State University | N/A |
| Completed | Immunity Duration of Rabies Vaccine and Booster Dose Effects at 10 Years Post-primary Vaccination NCT03774628 | Jiangsu Province Centers for Disease Control and Prevention | N/A |
| Unknown | Effect of ERIG Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune Response NCT03524417 | Queen Saovabha Memorial Institute | N/A |
| Unknown | Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in HIV-infected Adults NCT03228069 | Queen Saovabha Memorial Institute | N/A |
| Completed | Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. NCT02564471 | State University of New York - Upstate Medical University | Phase 4 |
| Completed | Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to NCT02912845 | Kamada, Ltd. | Phase 3 |
| Completed | Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen NCT02956421 | Yisheng Biopharma (Singapore) Pte. Ltd. | Phase 2 |
| Unknown | Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults NCT02547727 | Queen Saovabha Memorial Institute | N/A |
| Completed | A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell R NCT02545517 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly NCT02729168 | Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products | N/A |
| Completed | Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins NCT01641315 | Queen Saovabha Memorial Institute | N/A |
| Completed | Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis NCT02374814 | State University of New York - Upstate Medical University | Phase 4 |
| Completed | Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients NCT03093545 | Mahidol University | N/A |
| Completed | Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant NCT02657161 | Yisheng Biopharma (Singapore) Pte. Ltd. | Phase 1 |
| Completed | Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Va NCT02559921 | Beijing Chaoyang District Centre for Disease Control and Prevention | Phase 2 |
| Completed | The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans NCT02281396 | Beijing Center for Disease Control and Prevention | Phase 1 |
| Completed | Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults NCT02238756 | CureVac | Phase 1 |
| Completed | An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Adm NCT02139657 | Grifols Therapeutics LLC | Phase 1 |
| Completed | RNActive® Rabies Vaccine (CV7201) in Healthy Adults NCT02241135 | CureVac | Phase 1 |
| Completed | Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis R NCT01930357 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposur NCT01877395 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects NCT02040090 | Kamada, Ltd. | Phase 2 / Phase 3 |
| Completed | Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use NCT01784874 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older NCT01680016 | Novartis Vaccines | Phase 3 |
| Completed | A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects NCT02491541 | Jiangsu Province Centers for Disease Control and Prevention | Phase 3 |
| Completed | Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in NCT01662440 | Novartis Vaccines | Phase 3 |
| Completed | Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen NCT01622062 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response NCT01610362 | Queen Saovabha Memorial Institute | N/A |
| Completed | Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Po NCT01228383 | Crucell Holland BV | Phase 2 |
| Completed | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines W NCT01466387 | Novartis | Phase 3 |
| Completed | Simplifying the Rabies Pre-exposure Vaccination NCT01388985 | Institute of Tropical Medicine, Belgium | Phase 3 |
| Completed | Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules NCT01365494 | Novartis Vaccines | Phase 4 |
| Completed | Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies V NCT01339312 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination NCT01286493 | Queen Saovabha Memorial Institute | N/A |
| Completed | Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen NCT01137045 | Queen Saovabha Memorial Institute | Phase 4 |
| Unknown | Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine NCT01173302 | Peking University People's Hospital | Phase 4 |
| Terminated | Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Pos NCT01067079 | Novartis Vaccines | — |
| Completed | Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healt NCT00948272 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Rabies Immune Plasma Booster Study NCT01063140 | CSL Behring | — |
| Completed | Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Tw NCT00825305 | Novartis Vaccines | Phase 3 |
| Completed | Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies NCT00708084 | Crucell Holland BV | Phase 2 |
| Completed | A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabie NCT00656097 | Crucell Holland BV | Phase 2 |
| Completed | Immunogenicity and Safety of Verorab™ in Indian Population NCT00260351 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With J NCT00694460 | Novartis | Phase 2 |
| Completed | Rabies Immunization Concomitant With JEV in Children NCT00703521 | Mahidol University | Phase 2 |